Peer-Reviewed Publication
JHEP Rep2026;101958.July 15, 2026Journal Article
Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapies in chronic hepatitis B.
Cong Cheng1, Qing Xie2, Edward Gane3, Luis Enrique Morano Amado4, Sheng-Shun Yang5, Wenhong Zhang6, Jidong Jia7, Tarik Asselah8, Jia-Horng Kao9, Cheng-Yuan Peng10, Wei-Wen Su11, Tawesak Tanwandee12, Xieer Liang13, Maria Teresa Catanese14, Ethan Chen15, Farouk Chughlay14, Sudip Das16, Katerina Glavini14, Nelson Guerreiro14, Yan Huang17, Rémi Kazma14, Yukun Liang15, Claire McGeown14, Avinash Patil18, Ruchi Upmanyu16, Cynthia Wat16, Man-Fung Yuen19, Jinlin Hou20,
1Roche R&D Center (China) Ltd, Shanghai, China. Electronic address: hbv.program@roche.com.
2Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
3New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.
4Division of Infectious Diseases, University Hospital Álvaro Cunqueiro, Galicia Sur Research Institute (IIS Galicia Sur), Vigo, Spain.
5Division of Gastroenterology & Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
6Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
7Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
8Université de Paris-Cité, Department of Hepatology, AP-HP, Hôpital Beaujon, Centre de recherche sur l'inflammation, Inserm UMR1149, Paris, France.
9National Taiwan University Hospital, Taipei, Taiwan.
10Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
11Division of Gastroenterology and Hepatology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
12Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
13Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Organ Failure Research, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangdong Institute of Hepatology, Nanfang Hospital, Guangzhou, China.
14F. Hoffmann-La Roche Ltd, Basel, Switzerland.
15Roche (China) Holding, Ltd, Shanghai, China.
16Roche Products Ltd, Welwyn Garden City, United Kingdom.
17Roche R&D Center (China) Ltd, Shanghai, China.
18Parexel International, Hyderabad, India (external business partner for F. Hoffmann-La Roche Ltd, Basel, Switzerland.
19Department of Medicine and State Key Laboratory of Liver Research, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China. Electronic address: mfyuen@hku.hk.
20Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China; State Key Laboratory of Organ Failure Research, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangdong Institute of Hepatology, Nanfang Hospital, Guangzhou, China. Electronic address: jlhousmu@163.com.
Abstract
BACKGROUND & AIMS: Novel regimens aimed at achieving functional cure of chronic hepatitis B (CHB) in virologically suppressed participants require the withdrawal of nucleos(t)ide analogue (NA). However, data from clinical trials are limited.
METHODS: Piranga is a Phase 2 platform trial that evaluated 4 xalnesiran regimens with or without an immunomodulator in virologically suppressed participants…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans